Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05657639
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2022-12-12
Brief Title:
CAV Regimen for RR AML
Sponsor:
The First Affiliated Hospital of Soochow University
Organization:
The First Affiliated Hospital of Soochow University
Study Overview
Official Title:
Venetoclax Cladribine Plus Low-dose Cytarabine for RelapsedRefractory Acute Myeloid Leukemia a Multicenter Randomized Controlled Study
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the efficacy and safety of cladribine combined with low-dose cytarabine and venetoclax CAV regimen for relapsedrefractory acute myeloid leukemia RR AML
Detailed Description:
Patients with relapserefractory RR acute myeloid leukemia often show resistance to conventional chemotherapy and have dismal prognosis Salvage therapy using venetoclax combined with hypomethylation drugs achieved an overall response rate of only approximately 40 in RR AML Cladribine a purine analogue exerts cytotoxic proapoptotic and antiproliferative effects on AML cellsThe efficacy of cladribine plus cytarabine and venetoclax in RR AML has not been reported
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None